Check-Mate 141 Results: Nivolumab Improved OS in Patients With Recurrent or Metastatic Head and Neck Cancer
Not all patients who received nivolumab, however, had improved PFS.
Not all patients who received nivolumab, however, had improved PFS.
Doses of at least 60 mg yielded tumor reductions of 2% to 70% among 25 of the 30 evaluated patients.
At the time of final analysis, 192 of 302 patients had died.
One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.
Improvement in RFS was seen regardless of PD-L1 status.
Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Antigen-specific T cells increased in frequency in vaccinated mice.